I think you pose an irrelevant question. The tocilizumab “failure” has no connection whatsoever with BiT, no advantage for Bit . I keep reading all this stuff about this technology being a treatment for x, y or z but is there any evidence of any efficacy against C19? where’s the preclinical data that was talked about months ago? There seems a lot of hot air on this forum with this company.
And by the way, the Roche study missed its endpoints but the UK RECOVERY trial has continued with the tociliizumab arm.
I think you pose an irrelevant question. The tocilizumab...
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $5.671K | 298.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 512798 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1050263 | 5 |
View Market Depth
| Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
| BIT (ASX) Chart |